Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Thomas Filleron"'
Autor:
Nicolas Girard, Eric Pichon, David Planchard, Didier Debieuvre, Radj Gervais, Gaëlle Chenuc, Pascale Dubray-Longeras, J. Otto, Eric Dansin, Hervé Lena, Anne Madroszyk, Maurice Pérol, Thomas Filleron, Xavier Quantin, Lise Bosquet, Gaëtane Simon, Coureche Kaderbhai, Sophie Cousin, Sandrine Hiret, Christelle Clément-Duchêne, Christos Chouaid, Roland Schott
Publikováno v:
Targeted Oncology. 16:801-811
In Europe, few data regarding the characteristics of EGFR exon 20 insertion (20ins) mutations in non-small cell lung cancer (NSCLC) are available. Using a large real-world cohort, we assessed the incidence, characteristics, and outcomes of patients w
Autor:
Nathalie Andrieu-Abadie, Muriel Mounier, Pascale Olivier, Thierry Levade, Mathieu Virazels, Jean Milhès, Carine Dufau, Maha Ayyoub, Bruno Ségui, Cécile Pagès, Amélie Lusque, Jean-Pierre Delord, Stéphanie Brayer, Céline Colacios, Thomas Filleron, Anne Montfort, Nicolas Meyer
Publikováno v:
Clinical Cancer Research. 27:1037-1047
Purpose: TNF blockers can be used to manage gastrointestinal inflammatory side effects following nivolumab and/or ipilimumab treatment in patients with advanced melanoma. Our preclinical data showed that anti-TNF could promote the efficacy of immune
Autor:
Laurence Venat-Bouvet, Melanie White-Koning, William Jacot, Alicja Puszkiel, Jacques Robert, Etienne Chatelut, Hortense Laharie-Mineur, Thomas Filleron, Valérie Le Morvan, N. Dohollou, Marc Debled, Florence Dalenc, Chantal Bernard-Marty, Alexandre Evrard, Caroline Delmas, Fabienne Thomas, Henri Roché, Jean-Christophe Boyer, Cécile Arellano, Christelle Vachoux
Publikováno v:
Clinical Pharmacology & Therapeutics. 109:1244-1255
Variations in clinical response to tamoxifen (TAM) may be related to polymorphic cytochromes P450 (CYPs) involved in forming its active metabolite endoxifen (ENDO). We developed a population pharmacokinetic (PopPK) model for tamoxifen and six metabol
Autor:
Raphael Lopez, Sébastien Vergez, Amélie Lusque, Nicolas Meyer, Thomas Filleron, Jérôme Sarini, Emilien Chabrillac, Zoé Cavallier
Publikováno v:
Acta Dermato-Venereologica, Vol 99, Iss 13, Pp 1241-1245 (2019)
Ten to fifty percent of high-risk cutaneous squamous cell carcinoma may potentially metastasize. However, the concept of sentinel lymph node biopsy remains controversial for cutaneous squamous cell carcinoma. The aim of this study was to identify pro
Autor:
Ivan Bièche, Catherine Guerin, Marta Jimenez, Céline Callens, Daniel Nenciu, Thomas Filleron, Nathalie Droin, Olivier Tredan, Kadija Diop, Andrea Loehr, Anthony Gonçalves, Monica Arnedos, Cecile Vicier, Fabrice Andre, Pascal Jézéquel, Marie-Paule Sablin, Anne Patsouris
Publikováno v:
European journal of cancer (Oxford, England : 1990). 159
Background Breast cancer may present genomic alterations leading to homologous recombination deficiency (HRD). PARP inhibitors have proven their efficacy in patients with HER2-negative (HER2-) metastatic breast cancer (mBC) harbouring germline (g) BR
Autor:
Loic Mourey, Christophe Massard, Remy Delva, Joseph Ciccolini, Fabienne Thomas, Christine Chevreau, Thomas Filleron, Jean-Pierre Lotz, Stéphane Culine, Gwenaelle Gravis, Marine Gross-Goupil, Etienne Chatelut, Aude Flechon, Angelo Paci, Jacques-Olivier Bay, Jérôme Guitton, Sotheara Moeung, Yohan Gallois, Pascale Olivier, Bénédicte Lelièvre, Karim Fizazi
Publikováno v:
Cancer Medicine
Cancer Medicine, Wiley, 2021, 10 (7), pp.2250-2258. ⟨10.1002/cam4.3687⟩
Cancer Medicine, Vol 10, Iss 7, Pp 2250-2258 (2021)
Cancer Medicine, Wiley, 2021, 10 (7), pp.2250-2258. ⟨10.1002/cam4.3687⟩
Cancer Medicine, Vol 10, Iss 7, Pp 2250-2258 (2021)
Background High‐dose chemotherapy (HDCT) with TI‐CE regimen is a valid option for the treatment of relapsed advanced germ cell tumors (GCT). We report a phase II trial with therapeutic drug monitoring of carboplatin for optimizing area under the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb4da192febd5a6e0225a744c30d9760
https://hal.univ-angers.fr/hal-03208728
https://hal.univ-angers.fr/hal-03208728
Publikováno v:
Breast Cancer Research : BCR
Breast Cancer Research, Vol 23, Iss 1, Pp 1-11 (2021)
Breast Cancer Research, Vol 23, Iss 1, Pp 1-11 (2021)
Background The immune microenvironment (IME) of triple-negative breast cancers (TNBCs) and its modulation by neoadjuvant chemotherapy (NACT) remain to be fully characterized. Our current study aims to evaluate NACT-induced IME changes and assess the
Autor:
Thomas, Bachelot, Thomas, Filleron, Ivan, Bieche, Monica, Arnedos, Mario, Campone, Florence, Dalenc, Florence, Coussy, Marie-Paule, Sablin, Marc, Debled, Claudia, Lefeuvre-Plesse, Anthony, Goncalves, Marie-Ange Mouret, Reynier, William, Jacot, Benoit, You, Philippe, Barthelemy, Benjamin, Verret, Nicolas, Isambert, Xavier, Tchiknavorian, Christelle, Levy, Jean-Christophe, Thery, Tifenn, L'Haridon, Jean-Marc, Ferrero, Alice, Mege, Francesco, Del Piano, Etienne, Rouleau, Alicia, Tran-Dien, Julien, Adam, Amelie, Lusque, Marta, Jimenez, Alexandra, Jacquet, Ingrid, Garberis, Fabrice, Andre
Publikováno v:
Nature medicine. 27(2)
The impact of single-agent antibodies against programmed death-ligand 1 (PD-L1) as maintenance therapy is unknown in patients with metastatic breast cancer. The SAFIR02-BREAST IMMUNO substudy included patients with human epidermal growth factor recep
Autor:
Florent Puisset, Lizza E.L. Hendriks, Benjamin Besse, Celine Lefebvre, Elodie Martin, Julien Mazieres, A-M.C. Dingemans, Thomas Filleron, Remi Veillon, C. Raherisson, Roberto Ferrara, M. Sabatier, Laura Mezquita
Publikováno v:
Respiratory Medicine and Research
Respiratory Medicine and Research, Elsevier, 2020, 78, pp.100788-. ⟨10.1016/j.resmer.2020.100788⟩
Respiratory Medicine and Research, 2020, 78, pp.100788-. ⟨10.1016/j.resmer.2020.100788⟩
Respiratory medicine and research, 78:100788. Elsevier
Respiratory Medicine and Research, Elsevier, 2020, 78, pp.100788-. ⟨10.1016/j.resmer.2020.100788⟩
Respiratory Medicine and Research, 2020, 78, pp.100788-. ⟨10.1016/j.resmer.2020.100788⟩
Respiratory medicine and research, 78:100788. Elsevier
International audience; But: Les inhibiteurs du point de contrôle immunitaire (ICI) dirigés par le ligand antiprogrammé de la mort (PD1/PD-L1) sont largement utilisés pour traiter les patients atteints d’un cancer du poumon non à petites cellu
Autor:
Caroline Imbert, Stéphane Carpentier, Nathalie Andrieu-Abadie, Marlène Marcellin, Marine Fraisse, Pierre Brousset, Florie Bertrand, Elodie Martin, Céline Colacios, Bruno Ségui, Philippe Rochaix, Odile Burlet-Schiltz, Nicolas Meyer, Virginie Garcia, Thierry Levade, Anne Montfort, Laurence Lamant, Anne Gonzalez de Peredo, Elie Marcheteau, Julia Gilhodes, Thomas Filleron, Florent Puisset, Sophie Tartare-Deckert
Publikováno v:
Nature Communications
Nature Communications, Nature Publishing Group, 2020, 11 (1), pp.437. ⟨10.1038/s41467-019-14218-7⟩
Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
Nature Communications, 2020, 11 (1), pp.437. ⟨10.1038/s41467-019-14218-7⟩
Nature Communications 1 (11), 1-14. (2020)
Nature Communications, Nature Publishing Group, 2020, 11 (1), pp.437. ⟨10.1038/s41467-019-14218-7⟩
Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
Nature Communications, 2020, 11 (1), pp.437. ⟨10.1038/s41467-019-14218-7⟩
Nature Communications 1 (11), 1-14. (2020)
Immune checkpoint inhibitors (ICIs) have dramatically modified the prognosis of several advanced cancers, however many patients still do not respond to treatment. Optimal results might be obtained by targeting cancer cell metabolism to modulate the i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bbb121baf2f7bbf6da6d7924779f762
https://www.hal.inserm.fr/inserm-02492179/file/s41467-019-14218-7.pdf
https://www.hal.inserm.fr/inserm-02492179/file/s41467-019-14218-7.pdf